Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Boehringer Ingelheim
Colorcon
Merck
Mallinckrodt

Last Updated: August 11, 2022

CLINICAL TRIALS PROFILE FOR DICHLORPHENAMIDE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for dichlorphenamide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004802 ↗ Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders Completed Ohio State University Phase 3 1992-06-01 OBJECTIVES: I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic paralysis, and hypokalemic periodic paralysis.
NCT00004802 ↗ Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders Completed National Center for Research Resources (NCRR) Phase 3 1992-06-01 OBJECTIVES: I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic paralysis, and hypokalemic periodic paralysis.
NCT00494507 ↗ Hyper- and Hypokalemic Periodic Paralysis Study Completed National Institute of Neurological Disorders and Stroke (NINDS) Phase 3 2007-06-01 The purpose of this study is to compare Dichlorphenamide with placebo (an inactive substance) for prevention of episodes and for improvement of strength in hyperkalemic (HYP) and hypokalemic (HOP) periodic paralysis. This study will also look at the long-term effects of Dichlorphenamide in periodic paralysis.
NCT00494507 ↗ Hyper- and Hypokalemic Periodic Paralysis Study Completed University of Rochester Phase 3 2007-06-01 The purpose of this study is to compare Dichlorphenamide with placebo (an inactive substance) for prevention of episodes and for improvement of strength in hyperkalemic (HYP) and hypokalemic (HOP) periodic paralysis. This study will also look at the long-term effects of Dichlorphenamide in periodic paralysis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for dichlorphenamide

Condition Name

Condition Name for dichlorphenamide
Intervention Trials
Hypokalemic Periodic Paralysis 2
Hyperkalemic Periodic Paralysis 1
Paralysis, Hyperkalemic Periodic 1
Paramyotonia Congenita 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for dichlorphenamide
Intervention Trials
Paralysis, Hyperkalemic Periodic 2
Paralysis 2
Hypokalemic Periodic Paralysis 2
Myotonic Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for dichlorphenamide

Trials by Country

Trials by Country for dichlorphenamide
Location Trials
United States 8
Italy 1
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for dichlorphenamide
Location Trials
Texas 1
Ohio 1
New York 1
Missouri 1
Minnesota 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for dichlorphenamide

Clinical Trial Phase

Clinical Trial Phase for dichlorphenamide
Clinical Trial Phase Trials
Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for dichlorphenamide
Clinical Trial Phase Trials
Completed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for dichlorphenamide

Sponsor Name

Sponsor Name for dichlorphenamide
Sponsor Trials
National Institute of Neurological Disorders and Stroke (NINDS) 1
University of Rochester 1
Ohio State University 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for dichlorphenamide
Sponsor Trials
NIH 2
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
McKinsey
McKesson
Baxter
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.